INTRODUCTION
Clinical governance is an evolving concept developed by the UK government to cover the introduction of formal accountability for quality in the UK National Health Service (NHS). Although its impact on medical staff will be greatest, because of recent cases attracting much media attention, there are implications for staff throughout the NHS. The concept was mentioned in the government white paper The New NHS: Modern, Dependable in December 1997 1 and introduced in outline terms in June 1998 in the document A First Class Service: Quality in the New NHS. 2 However, formal guidance was only issued in March 1999 3 and a lot of documentation has yet to be issued. Therefore, this brief look at clinical governance has to be considered as an interim view based on the broad principles laid out so far in the initial documents. The views in the article were formed by my participation in a`focus group' at the Northern General Hospital, charged with laying the groundwork for a system of clinical governance within the Trust.
Clinical governance is only de®ned in the main government publications 1±3 in terms of its scope (see Table 1 ), so a plethora of de®nitions have been published, often re¯ecting the interests of the group concerned. My personal de®nition is: clinical governance is a term which describes the creation in a health care environment of a framework to ensure that the optimum quality of care is delivered to the population and to provide assurance of this to both the government and the population'. A much shorter working de®nition could be`total quality assurance in a health care environment'. By de®ning clinical governance in terms of quality assurance, it becomes much more intelligible to members of the clinical chemistry profession who are used to working out the implication of quality assurance in clinical chemistry, particularly in the sphere of accreditation. Clinical governance is intended to embrace all aspects of health care delivery but the principal emphases have been placed on optimization of clinical care, accountability for quality of care, monitoring clinical activity and professional development. These are dealt with in turn in the following sections.
OPTIMIZATION OF CLINICAL CARE
The core of the agenda is that clinical care should be optimized for all patients in all locations at all levels of care. The concept that optimized procedures will lead to quality and consistency of product is fundamental in manufacturing, and familiar in the high street in products as diverse as the McDonald's burger and Japanese cars. In contrast, in the area of clinical care in the UK idiosyncrasy is the norm, and having 101 ways of looking after patients with the same condition is not unusual. In Japan, however, a highly structured approach to the diagnosis and management of gastric cancer has achieved remarkable results. This approach could produce bene®ts for patients if transferred to this country. 4 The attitude towards structured protocols is changing, as shown by the introduction of standard operating procedures for clinical activities (under the Calman±Hine initiative) in a drive for improvement in the results of cancer care. Similarly, in clinical laboratories, standard operating procedures are now the accepted norm and this is one of the means by which precision and reliability of assays has considerably improved. This is not to deny that the clinician must be on the lookout for the patient for whom the standard procedure is inappropriate. However, it is now being realized that consistency of outcome does follow consistency of process and it is becoming more common for patient`work up' and treatment procedures to be standardized or`protocoldriven'. There are three major driving forces for optimization of clinical care.
shown not to work and ignoring procedures which have been shown to work is bad medical practice. However, there is often dif®culty in determining what the appropriate evidencebased procedures are for given clinical situations. Information is often not widely available and may be dif®cult to access. A new organization, the National Institute for Clinical Excellence (NICE), which began operations in April 1999, will integrate information from a variety of sources through multi-professional appraisal groups to`produce clear guidance for clinicians about which treatments work best for which patients'. 2 NICE will produce guidelines for the management of certain diseases or conditions and guidance on the appropriate use of particular interventions. Its scope will include therapeutic products and medical devices, therapeutic interventions and programmes of care, products and processes to diagnose and prevent diseases in individuals, and population screening. The results from health technology assessment reviews undertaken within the NHS Research and Development programme will be included in their advice. 5 It is hoped that propagation of good practice guidelines by NICE will lead to equality of treatment across the country (e.g. an end to`postcode prescribing') for major conditions. In addition, National Service Frameworks (NSF) (see Table 2 ) will set national standards and de®ne service models for speci®c diseases or services. There is an emphasis throughout on the propagation of information on clinical effectiveness, particularly through increasing the availability of existing databases such as the Cochrane collection and through the proposed National Electronic Library for Health. 6 However, the dif®culties in getting evidence into widespread clinical practice are acknowledged, and to be successful, strategies will have to be adequately resourced. 7 Although there may be little impact initially on laboratory services, we may ®nd ourselves obliged to offer certain tests, and perhaps delete others from our repertoire. For example, total cholesterol to high-density lipoprotein ratios are now used in a number of algorithms to assist in cardiovascular disease risk assessment, but are not available in all UK laboratories at present.
Good practice
There are many areas of good practice within the NHS but these are often not widely known. The government intends to publish examples of good practice by highlighting them as`beacon services'. Beacon services will be given funding to enable them to disseminate their good practice. The areas in which examples of good practice are currently sought are listed in Table 3 . 
ACCOUNTABILITY FOR QUALITY

Management responsibility
The thrust behind clinical governance is to improve the whole health care system, not just get the medical part right. Thus, the Chief Executive has a statutory responsibility for quality, although individual patient care will remain the responsibility of the staff dealing with those patients. Trusts should have already identi®ed a lead clinician and they will be setting up a process for ensuring that the lines of responsibility for clinical governance are clear for all health professionals. Trusts were required to ensure that appropriate structures to oversee clinical governance existed from April 1999. At the Northern General Hospital, the heads of the individual laboratories managed by the Trusts are accountable for clinical governance to me, as chair of the clinical directorate, and will report quarterly on clinical governance matters at our directorate meeting. Other structures concerned with quality also need to feed into the clinical governance process. The interim Northern General Hospital arrangements for this are shown in Fig. 1 . This is only the initial con®guration and will be modi®ed by experience. My responsibility for clinical governance means having to be aware of the performance of the other laboratories, notably in EQA. For disciplines in the directorate with personal EQA such as histopathology, I will need to be aware of performance issues, but the degree to which I will be aware of details of personal performance has yet to be established. I am responsible for clinical governance through clinical lines of accountability to the Medical Director and, ultimately, the Chief Executive. However, the main reporting mechanism (see Fig. 1 ) is through the clinical governance committee, which acts as the monitor of clinical governance matters for the Trust in the same way as the Audit Committee monitors ®nancial performance. In Trusts where pathology is linked with non-clinical disciplines, the heads of the laboratories will need to ensure that clinical governance operates through the clinical lines of accountability.
Reporting arrangements
The NHS Executive Regional Of®ces will oversee the implementation of local clinical governance arrangements. Trusts will already have been in contact with them to report on their capacity for implementing clinical governance across the organization and to provide them with an action plan for doing so. Within organizations, clinical governance issues should be reported to the Board. Health Authorities, primary care groups, primary care trusts and NHS Trusts are required to report on clinical governance in their annual report, ®rstly in the report for 1999/2000.
Professional self-regulation
The government has emphasized that professional self-regulation will continue. The professions are in the process of setting up procedures to assist in monitoring professional performance. The intention is that such procedures take effect at an early stage, before patients are harmed. As the chief target of public concern, medical staff have been in the front line of changes in procedures. This has led to an emphasis by the General Medical Council (GMC) on revalidation, 9 the regular demonstration by all registered doctors that they remain ®t to practise in their chosen ®eld, which will be linked with continued registration. The details of this have still to be worked out but could include a review of indicators of clinical performance as revealed by clinical monitoring (see below), continuing professional development (including educational activity) and participation in audit. It is likely that evidence would be periodically submitted to the GMC to con®rm registration. Various models have been discussed recently by the Academy of the Medical Royal Colleges. 10 The GMC has indicated that it is aiming to have a model for revalidation approved by spring 2001. 9 Although the details are being revealed for medical staff because of their prominence in the political and public consciousness, A First Class Service is written to include all health professionals, so registered clinical scientists and biomedical scientists are likely to be included in due course.
MONITORING CLINICAL ACTIVITY
Clinical indicators
Clinical activity is already measured by a number of indicators which are published regularly as the much criticized league tables. It is intended that clinical activity will continue to be monitored much more closely, with particular emphasis on patient outcomes, including complication and re-admission rates. Wherever possible, results are expected to be linked to the clinicians concerned in the patients' treatment, e.g. the outcome of operations will be linked to those clinicians involved in the operation. The outcome in speci®ed medical conditions such as myocardial infarction will be monitored as well. Concerns about validity of currently collected data 11 are acknowledged and it is anticipated that it will take time to develop a comprehensive set of indicators. In addition, risk adjustments to standardize for factors such as age, severity, case mix and concurrent illnesses will be required. Nevertheless, the government feels that the public have a right to know about the performance of the public service that they are using and funding. A further important element in monitoring of quality in the NHS will be the National Survey of Patient and User Experience. This will be conducted in every Health Authority annually and the results will be published locally and nationally.
Audit
Conventional clinical audit will continue to be undertaken and will inform local practice in the normal way. However, Trusts will be expected to audit how they perform against the standards laid down in the National Service Frameworks. In addition, Trusts are expected to monitor complaints and have a procedure for critical incident monitoring in order to prevent adverse experience or recurrence of critical problems. Laboratories need to monitor adverse incidents (for example, sample misidenti®cation) and learn to minimize risk by studying them, and setting procedures in place to prevent them.
National con®dential enquiries
At the moment, participation in the national con®dential enquiries (perioperative death, stillbirths and deaths in infancy, maternal deaths, suicide and homicide by people with mental illness) is voluntary. In future, participation in these enquiries will be mandatory.
Commission for Health Improvement
The principal organization monitoring clinical governance will be the Commission for Health Improvement. The details had not yet been worked out at the time of writing. However, it is clear that the commission will have wide powers, with the emphasis on measuring quality. It will have access to the results of the National Survey of Patient and User Experience as well as the data from the monitoring of clinical activity taking place throughout the NHS. The Commission for Health Improvement will visit each NHS and primary care Trust over a period of about 3 to 4 years. The programme will be informed by data collated by the Regional Of®ce, and particular visits may also be triggered by quality problems within Trusts. The work should be coordinated with the audit commission work programme within the NHS, although whether it will be coordinated with or will duplicate clinical pathology accreditation (CPA) is not yet clear.
CONTINUING PROFESSIONAL DEVELOPMENT
Lifelong learning
A key element in clinical governance is the emphasis on a culture that values lifelong learning and the part it plays in improving quality. Thus, undirected continuing medical education points accumulation will be replaced by continuing professional development (CPD), although professional education will continue to be a key part in demonstrating ®tness to practise. To this end, some royal colleges have already produced CPD portfolios for staff 12, 13 and further schemes will follow for other professional staff. CPD is intended to be more integrated into the whole quality assurance process involving audit, clinical effectiveness, and research and development, and involve all health professionals in the service.
Workforce planning
The emphasis on workforce planning is for it to be directed towards the goals of the local health service. It is intended that personal professional expertise and activity will be directed towards meeting the local needs of the service, particularly quality aspects and patient expectations, as well as personal professional interest. This will take the form of a personal professional development plan for each health professional in the service. Training and development plans are to be in place for the majority of health professional staff by April 2000.
The imposition of directed personal development planning will be quite a change of culture for most health professions. It will also mean that once they have achieved a permanent professional position, all health professionals will be expected to continue their personal development and remain up-to-date and knowledgeable about advances in their ®eld. Although perhaps most novel in its impact on established medical staff, 14 with their rigid professional hierarchy, it is a cultural change which will have implications all the way down to the training of students, and a change which will involve staff of all professions.
Professional performance procedures
There is increasing sensitivity about the performance of professionals, and monitoring of professional performance will be part of development planning, identifying areas where further training or education may be necessary. Trusts have to have clear procedures in place for staff to report any concerns about colleagues' professional conduct and performance. Other concerns may be raised by clinical monitoring procedures, audit or complaints monitoring. Where the above processes identify substandard performance, procedures have to be in place within the Trust to deal with poor performance, expeditiously, fairly and effectively to prevent patient harm.
CONCLUSION
The impression is that clinical governance is here to stay. The drive for quality is far reaching, and considerable effort will be expended in ensuring that poor performance, where identi®ed, is not allowed to continue. Both the Regional Of®ces and the Commission for Health Improvement can be called in at short notice to review problems. Whether the revolution will be pursued with the vigour with which it was launched remains to be seen, and it may, like other initiatives, be allowed to quietly ®nd its own level once ministerial agendas move on. Other bodies, like the General Medical Council and some royal colleges, have changed their procedures to support clinical governance 15 . At the time of writing, the Royal College of Pathologists has yet to produce a de®nitive view.
There is no doubt that there are considerable cost implications for the NHS. Quite apart from the cost of setting up a new institute and commission, there is the cost of monitoring in particular, and the time given to clinical governance procedures for staff involved in committees and in the peer review processes. The cost of setting up and running external quality assurance and accreditation procedures in those areas where such procedures are underdeveloped are also not insubstantial, as pathology laboratories can testify. There are no new resources available for any of this, and concern has been raised at the practicability of applying a whole new set of procedures to hard-pressed NHS staff. 16 The implications for laboratories are as yet unclear. Laboratory services are, however, well placed to deal with some of the aspects of clinical governance with objective quality data in the form of EQA and accreditation. Nevertheless, laboratories can not afford to be complacent. At the moment, the extent of participation in such activities is discretionary but whether it stays that way remains to be seen. My personal view is that while accreditation through CPA is good at identifying shortcomings in process, procedures and facilities, it is not so good at identifying the quality of a clinical service, particularly the clinical advice provided by a department. For effective quality monitoring, additional audit may need to be directed at this.
For members of staff, the changes are intended to help them to provide optimum care and to aid professional self-development. However, the collection of poorly validated data targeted at clinical performance is bound to be threatening to individuals until appropriate performance measures are agreed and data quality radically improved. Cynically, the authorities may be using the personal interests of those most directly involved to drive the much-needed improvement in data quality. How all this will be achieved without additional resources is a trick that has yet to be revealed. The annual commitment of time required to undertake clinical governance procedures for my pathology management team will be at least the equivalent of a week of professional time. My colleagues will collectively lose a similar amount of time. Although direct patient care is unlikely to be penalized, other quality activities such as research, teaching and reading could be compromised. Like most of my colleagues concerned about providing the optimum service, I am prepared to give clinical governance a try but have some concerns that the disruption and bureaucracy associated with the changes may outweigh the gains in clinical quality. By far the biggest contribution to quality in the NHS is the continuing high standards set for themselves by professionals within the service. It remains to be seen whether the gain in quality from following clinical governance procedures will be negated by compromise in these standards, due to further pressure imposed on staff by those same procedures.
